Replies to post #202089 on Biotech Values

[DewDiligence]

INNL -52%/AH on FDA Refusal-to-File letter:

http://finance.yahoo.com/news/innocoll-receives-refusal-file-letter-220000342.html

In the Refusal to File letter, the FDA indicated among other things, that XARACOLL should be characterized as a drug/device combination, which would require that the Company submit additional information.

There was a pretty big failure in communication, evidently.

Raising money at $7/sh in mid 2016 (#msg-123365155) looks pretty smart now.